2D1J
Factor Xa in complex with the inhibitor 2-[[4-[(5-chloroindol-2-yl)sulfonyl]piperazin-1-yl] carbonyl]thieno[3,2-b]pyridine n-oxide
Summary for 2D1J
Entry DOI | 10.2210/pdb2d1j/pdb |
Related | 1V3X 1WU1 |
Descriptor | Coagulation factor X, heavy chain, Coagulation factor X, light chain, CALCIUM ION, ... (5 entities in total) |
Functional Keywords | glycoprotein, hydrolase, serine protease, plasma, blood coagulation factor, protein inhibitor complex, calcium-binding |
Biological source | Homo sapiens (human) More |
Cellular location | Secreted: P00742 P00742 |
Total number of polymer chains | 2 |
Total formula weight | 32750.64 |
Authors | Suzuki, M. (deposition date: 2005-08-24, release date: 2006-08-24, Last modification date: 2024-11-06) |
Primary citation | Komoriya, S.,Haginoya, N.,Kobayashi, S.,Nagata, T.,Mochizuki, A.,Suzuki, M.,Yoshino, T.,Horino, H.,Nagahara, T.,Suzuki, M.,Isobe, Y.,Furugoori, T. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites. Bioorg.Med.Chem., 13:3927-3954, 2005 Cited by PubMed Abstract: Compound 7 was identified as the active metabolite of 6 by HPLC and mass spectral analysis. Modification of lead compound 7 by transformation of its N-oxide 6-6 biaryl ring system and fused aromatics produced a series of non-basic fXa inhibitors with excellent potency in anti-fXa and anticoagulant assays. The optimized compounds 73b and 75b showed sub to one digit micromolar anticoagulant activity (PTCT2). Particularly, anti-fXa activity was detected in plasma of rats orally administered with 1mg/kg of compound 75b. PubMed: 15911309DOI: 10.1016/j.bmc.2005.04.006 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.2 Å) |
Structure validation
Download full validation report
